← All trials
NCT04055233
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2015
- Primary completion
- Sep 10, 2018
- Completion date
- Oct 20, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 456
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Humboldt UniversityLead sponsor
- Humboldt UniversitySponsor investigator
- Humboldt UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.